The Lawrence and Isabel Barnett Drug Development Program (2023) funded by the ALS Association offers funding for investigators in industry or academia worldwide focused on the preclinical assessment of therapeutics for amyotrophic lateral sclerosis (ALS).
The following drug discovery projects are of greatest interest:
• In vivo efficacy testing of therapeutic candidates (pharmacological treatments, biological therapies, or gene therapy) in models of ALS.
• Studies on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, and target engagement.
• Other IND enabling studies
This funding provides $500,000 USD total costs for two years, with indirect costs limited to 10%.
A letter of intent is due on March 30, 2023. Full applications are by invitation only and due on June 1, 2023.
